0RD1.LSE Camurus AB
- Market cap
- SEK 25.1B
- P/E
- -
- P/B
- -
- ROE
- 16.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0RD1.LSE undervalued?
Graham numberThe Graham number of Camurus AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Camurus AB fundamental analysis
No fundamental analysis for Camurus AB yet.
Camurus AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and…
Full company profileCamurus AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Camurus AB annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 114M | 54.3M | 49.3M | 106M | 336M | 601M | 956M | 1.72B | 1.87B | 2.27B | 2.47B |
| Gross Profit | 108M | 48.9M | 40.1M | 75.4M | 292M | 511M | 850M | 1.59B | 1.74B | 2.08B | 2.28B |
| Operating Income | -103M | -242M | -288M | -361M | -207M | -113M | 70.5M | 526M | 471M | 884M | 963M |
| EBITDA | -99.8M | -239M | -285M | -353M | -197M | -97.7M | 87.6M | 545M | 568M | 909M | 991M |
| Net Income | -81.0M | -191M | -235M | -290M | -167M | -90.4M | 55.6M | 431M | 428M | 736M | 769M |
| EPS | -1.99 | -4.68 | -5.68 | -6.23 | -3.18 | -1.66 | 1.01 | 7.50 | 7.20 | 12 | 13 |
| Balance Sheet | |||||||||||
| Total Assets | 645M | 480M | 369M | 781M | 1.05B | 1.09B | 1.31B | 1.91B | 3.76B | 4.74B | 5.31B |
| Total Liabilities | 80.2M | 95.4M | 117M | 149M | 205M | 239M | 313M | 415M | 467M | 519M | 626M |
| Shareholders' Equity | 564M | 385M | 252M | 632M | 847M | 849M | 995M | 1.49B | 3.29B | 4.24B | 4.68B |
| Cash & Short-term Investments | 509M | 315M | 134M | 359M | 462M | 412M | 566M | 1.19B | 2.85B | 3.73B | 4.07B |
| Total Debt | - | - | - | 27.3M | 25.5M | 25.7M | 26.2M | 24.5M | 17.0M | 106M | 108M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -208M | -203M | -274M | -404M | -239M | -143M | 101M | 607M | 388M | 869M | 793M |
| Capital Expenditure | 4.57M | 2.14M | 4.76M | 25.9M | 3.33M | 3.99M | 1.91M | 9.19M | 27.6M | 138M | 162M |
| Free Cash Flow | -212M | -205M | -279M | -430M | -242M | -147M | 99.3M | 598M | 360M | 731M | 632M |
| Ratios | |||||||||||
| ROE | -14.3% | -49.5% | -93.0% | -45.9% | -19.7% | -10.7% | 5.6% | 28.9% | 13.0% | 17.4% | 16.4% |
| ROA | -12.6% | -39.7% | -63.6% | -37.1% | -15.9% | -8.3% | 4.2% | 22.6% | 11.4% | 15.5% | 14.5% |
| Net Profit Margin | -71.2% | -350.9% | -475.8% | -274.5% | -49.8% | -15.1% | 5.8% | 25.1% | 22.9% | 32.5% | 31.1% |
| Debt to Equity | - | - | - | 0.04x | 0.03x | 0.03x | 0.03x | 0.02x | 0.01x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Camurus AB dividends
Camurus AB has not paid dividends in the last 9 fiscal years.
Last stock split: 1113:1019 on Mar 6, 2019.
Who owns Camurus AB
- Insiders 33.12%
- Institutions 43.74%
- Public & others 23.15%
- Shares outstanding 38.4M
- Free float 39.5M
Camurus AB company profile
- Company name
- Camurus AB
- Ticker
- 0RD1.LSE
- ISIN
- SE0007692850
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 316
- Fiscal year end
- December
- Address
- Rydbergs torg 4, Lund, Sweden, 224 84
- Phone
- 46 4 62 86 57 30
- Website
- camurus.com
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Camurus AB management
10- Mr. Fredrik TibergPresident, CEO, CSO & Director · born 1963
- Mr. Anders Fink Vadsholt M.B.A., M.Sc.Chief Financial Officer · born 1969
- Ms. Susanne LagerlundVice President of Technical Operations · born 1968
- Mr. Rein Piir B.Sc.Vice President of Investor Relations · born 1958
- Bo A. C. TarrasWahlbergVP of Legal & Group General Counsel · born 1975
- Ms. Jane Buus Laursen Ph.D.Chief Corporate Development Officer · born 1975
- Ms. Maria LundqvistGlobal Head of Human Resources · born 1966
- Mr. Markus JohnssonSenior Vice President of R&D · born 1972
- Mr. Fredrik JoabssonChief Business Development Officer · born 1972
- Mr. Richard JamesonChief Commercial Officer · born 1964